Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.

Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF.

J Clin Oncol. 2016 Jul 10;34(20):2404-15. doi: 10.1200/JCO.2016.66.6487. Epub 2016 May 9.

2.

Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord.

Wang Y, Springer S, Zhang M, McMahon KW, Kinde I, Dobbyn L, Ptak J, Brem H, Chaichana K, Gallia GL, Gokaslan ZL, Groves ML, Jallo GI, Lim M, Olivi A, Quinones-Hinojosa A, Rigamonti D, Riggins GJ, Sciubba DM, Weingart JD, Wolinsky JP, Ye X, Oba-Shinjo SM, Marie SK, Holdhoff M, Agrawal N, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C.

Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9. doi: 10.1073/pnas.1511694112. Epub 2015 Jul 20.

3.

Brain tumor mutations detected in cerebral spinal fluid.

Pan W, Gu W, Nagpal S, Gephart MH, Quake SR.

Clin Chem. 2015 Mar;61(3):514-22. doi: 10.1373/clinchem.2014.235457. Epub 2015 Jan 20.

4.

Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.

Fontanilles M, Marguet F, Bohers É, Viailly PJ, Dubois S, Bertrand P, Camus V, Mareschal S, Ruminy P, Maingonnat C, Lepretre S, Veresezan EL, Derrey S, Tilly H, Picquenot JM, Laquerrière A, Jardin F.

Oncotarget. 2017 Jul 18;8(29):48157-48168. doi: 10.18632/oncotarget.18325.

5.

Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.

Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM.

Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.

6.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.

Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, Park YS, Lim HY, Eltoukhy H, Kang WK, Lee WY, Kim HC, Park K, Lee J, Talasaz A.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.

7.

Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases.

Li Y, Pan W, Connolly ID, Reddy S, Nagpal S, Quake S, Gephart MH.

J Neurooncol. 2016 May;128(1):93-100. doi: 10.1007/s11060-016-2081-5. Epub 2016 Mar 9.

8.

Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.

Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P, Egorin MJ.

J Natl Cancer Inst. 1995 Jul 19;87(14):1077-81.

PMID:
7616600
9.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.

Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.

10.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J.

Nat Commun. 2015 Nov 10;6:8839. doi: 10.1038/ncomms9839.

11.

Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC.

Oncotarget. 2017 Jan 31;8(5):7989-7998. doi: 10.18632/oncotarget.14008.

12.

Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients.

Shi W, Lv C, Qi J, Zhao W, Wu X, Jing R, Wu X, Ju S, Chen J.

J Mol Neurosci. 2012 Mar;46(3):470-5. doi: 10.1007/s12031-011-9617-0. Epub 2011 Sep 1.

PMID:
21881830
13.
14.

Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.

Shah RH, Scott SN, Brannon AR, Levine DA, Lin O, Berger MF.

Cancer Cytopathol. 2015 May;123(5):289-97. doi: 10.1002/cncy.21522. Epub 2015 Feb 5.

15.

Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.

Nakauchi C, Kagara N, Shimazu K, Shimomura A, Naoi Y, Shimoda M, Kim SJ, Noguchi S.

Clin Breast Cancer. 2016 Oct;16(5):418-423. doi: 10.1016/j.clbc.2016.05.004. Epub 2016 May 14.

PMID:
27265061
16.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L.

Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7.

17.

Tissue polypeptide antigen activity in cerebrospinal fluid: a marker of central nervous system metastases of breast cancer.

Bach F, Soletormos G, Dombernowsky P.

J Natl Cancer Inst. 1991 Jun 5;83(11):779-84.

PMID:
2041052
18.

Creatine kinase-BB in the cerebrospinal fluid as a marker of CNS metastases and leptomeningeal carcinomatosis in patients with breast cancer.

Bach F, Bach FW, Pedersen AG, Larsen PM, Dombernowsky P.

Eur J Cancer Clin Oncol. 1989 Dec;25(12):1703-9.

PMID:
2632253
19.

Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.

Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, Iuchi T, Yokoi S, Kimura H, Iizasa T.

J Thorac Oncol. 2011 Jul;6(7):1215-20. doi: 10.1097/JTO.0b013e318219aaae.

20.

Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.

Sanchez R, Ayala R, Alonso RA, Martínez MP, Ribera J, García O, Sanchez-Pina J, Mercadal S, Montesinos P, Martino R, Barba P, González-Campos J, Barrios M, Lavilla E, Gil C, Bernal T, Escoda L, Abella E, Amigo ML, Moreno MJ, Bravo P, Guàrdia R, Hernández-Rivas JM, García-Guiñón A, Piernas S, Ribera JM, Martínez-López J.

Ann Hematol. 2017 Jul;96(7):1069-1075. doi: 10.1007/s00277-017-3002-1. Epub 2017 Apr 27.

Supplemental Content

Support Center